Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STATURE: Secukinumab IV vs SC in Psoriasis Partial Responders
NCT01412944Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Dec 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01412944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01412944.